1991
The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland
DeVita V. The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland. Annals Of Oncology 1991, 2: 93-106. PMID: 2054322, DOI: 10.1093/oxfordjournals.annonc.a057892.Peer-Reviewed Original Research
1983
The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer
Devita V. The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983, 51: 1209-1220. PMID: 6825044, DOI: 10.1002/1097-0142(19830401)51:7<1209::aid-cncr2820510707>3.0.co;2-j.Peer-Reviewed Original ResearchAdvances in cancer therapeutics: chemotherapy.
DeVita V. Advances in cancer therapeutics: chemotherapy. Progress In Clinical And Biological Research 1983, 132A: 47-69. PMID: 6634746.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCell CycleDrug ResistanceHumansMutationNeoplasmsPhenotypeConceptsTumor massEffectiveness of combination chemotherapyResistance to anti-cancer drugsCancer chemotherapyInvariable inverse relationshipPathways of drug resistanceOutcome of cancer chemotherapyOutcome of surgeryResistance to chemotherapyCell numberHistory of cancerNatural history of cancerOrigin of human cancerCombination chemotherapyAnti-cancer drugsLocal treatmentChemotherapyDrug resistanceHuman malignanciesRadiotherapyCancer therapeuticsNatural historyHuman cancersSurgeryCancerThe cure of Hodgkin's disease with drugs.
DeVita V, Hubbard S, Moxley J. The cure of Hodgkin's disease with drugs. Advances In Internal Medicine 1983, 28: 277-302. PMID: 6188346.Peer-Reviewed Original Research
1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologic
1975
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Canellos G, Young R, Neiman P, DeVita V. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood 1975, 45: 197-203. PMID: 1054609, DOI: 10.1182/blood.v45.2.197.bloodjournal452197.Peer-Reviewed Original ResearchConceptsTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanIncreased skin pigmentationMyelosuppressive actionRemission inductionMaintenance therapyMedian survivalMedian durationBlastic transformationPulmonary fibrosisBusulfanRandomized comparisonChronic phaseLeukocyte countDibromomannitolPatientsCytological dysplasiaCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
Devita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAlkylating AgentsAntineoplastic AgentsBinding, CompetitiveBreast NeoplasmsBurkitt LymphomaChoriocarcinomaCyclophosphamideDrug ResistanceDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLeukemia, LymphoidNeoplasm MetastasisNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPregnancy
1973
The Use of Drugs in Combination for the Treatment of Cancer — Rationale and Results
DeVita V, Schein P. The Use of Drugs in Combination for the Treatment of Cancer — Rationale and Results. New England Journal Of Medicine 1973, 288: 998-1006. PMID: 4348752, DOI: 10.1056/nejm197305102881905.Peer-Reviewed Original ResearchAnimalsAntineoplastic AgentsBreast NeoplasmsChildDose-Response Relationship, DrugDrug ResistanceDrug SynergismFemaleGastrointestinal NeoplasmsHodgkin DiseaseHumansLeukemia L1210Leukemia, LymphoidLeukemia, Myeloid, AcuteLymphomaMaleModels, BiologicalNeoplasmsNeuroblastomaRemission, SpontaneousTesticular NeoplasmsTime FactorsWilms Tumor